Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 146.73
FLML's Cash to Debt is ranked higher than
54% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. FLML: 146.73 )
Ranked among companies with meaningful Cash to Debt only.
FLML' s Cash to Debt Range Over the Past 10 Years
Min: 0.08  Med: 12.7 Max: N/A
Current: 146.73
Equity to Asset 0.15
FLML's Equity to Asset is ranked lower than
89% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. FLML: 0.15 )
Ranked among companies with meaningful Equity to Asset only.
FLML' s Equity to Asset Range Over the Past 10 Years
Min: -0.13  Med: 0.53 Max: 0.8
Current: 0.15
-0.13
0.8
Z-Score: 1.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 36.92
FLML's Operating margin (%) is ranked higher than
94% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. FLML: 36.92 )
Ranked among companies with meaningful Operating margin (%) only.
FLML' s Operating margin (%) Range Over the Past 10 Years
Min: -635.24  Med: -33.09 Max: 41.25
Current: 36.92
-635.24
41.25
Net-margin (%) 17.15
FLML's Net-margin (%) is ranked higher than
87% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. FLML: 17.15 )
Ranked among companies with meaningful Net-margin (%) only.
FLML' s Net-margin (%) Range Over the Past 10 Years
Min: -574.66  Med: -29.23 Max: 23.47
Current: 17.15
-574.66
23.47
ROE (%) 57.25
FLML's ROE (%) is ranked higher than
98% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. FLML: 57.25 )
Ranked among companies with meaningful ROE (%) only.
FLML' s ROE (%) Range Over the Past 10 Years
Min: -1103.89  Med: -25.52 Max: 86.48
Current: 57.25
-1103.89
86.48
ROA (%) 13.46
FLML's ROA (%) is ranked higher than
94% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. FLML: 13.46 )
Ranked among companies with meaningful ROA (%) only.
FLML' s ROA (%) Range Over the Past 10 Years
Min: -58.46  Med: -12.4 Max: 20.89
Current: 13.46
-58.46
20.89
ROC (Joel Greenblatt) (%) 2773.70
FLML's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. FLML: 2773.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FLML' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -662.22  Med: -41.19 Max: 3856.65
Current: 2773.7
-662.22
3856.65
Revenue Growth (3Y)(%) 56.40
FLML's Revenue Growth (3Y)(%) is ranked higher than
91% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. FLML: 56.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
FLML' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.4  Med: -0.1 Max: 56.4
Current: 56.4
-32.4
56.4
» FLML's 10-Y Financials

Financials (Next Earnings Date: 2017-03-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

FLML Guru Trades in Q4 2015

Steven Cohen 67,012 sh (New)
» More
Q1 2016

FLML Guru Trades in Q1 2016

Steven Cohen 358,958 sh (+435.66%)
» More
Q2 2016

FLML Guru Trades in Q2 2016

Steven Cohen 461,839 sh (+28.66%)
» More
Q3 2016

FLML Guru Trades in Q3 2016

Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FLML

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CLDX, NAS:CLSD, NAS:MCRB, NAS:BCRX, NAS:VSAR, NAS:CTMX, NAS:PTGX, NAS:PTCT, NAS:CRIS, NAS:AGEN, NAS:PDLI, NAS:SELB, NAS:NSTG, NAS:NERV, NAS:XBIT, OTCPK:HNSBF, NAS:TLGT, NAS:CYNA, NAS:CYTK, NAS:BOLD » details
Traded in other countries:FL3.Germany,
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in drug delivery and formulation to develop safer and more efficacious pharmaceutical products to address unmet medical needs and reduce overall healthcare costs.

Flamel Technologies SA was incorporated as a Societe Anonyme or SA, a form of corporation under the laws of the Republic of France in August 1990 as Flamel Technologies S.A. The Company is a specialty pharmaceutical company with a history in drug delivery, working on the development of safer and more efficacious formulations. The acquisition of Éclat on March 13, 2012 has created a more vertically integrated company, benefiting from greater development and commercial expertise and more near-term and mid-term potential value creating catalysts. Since its acquisition of Eclat, Flamel is now engaged in not only on the development and licensing of versatile, proprietary drug delivery platforms but also on the development of novel, high-value products based on those delivery platforms. Bloxiverz, the Company first NDA approval from the portfolio of Eclat products acquired in March 2012. Bloxiverz's NDA was filed in August 2012 and approved by the FDA on May 2013. The launch of Bloxiverz commenced in July 2013. Bloxiverz is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Bloxiverz is the first and only FDA-approved version of neostigmine methylsulfate, even though other versions of neostigmine have been on the market as unapproved, grandfathered products under the Food, Drug and Cosmetic Act of 1938. Coreg CR, the lead product using its Micropump drug delivery platform. Coreg CR is an extended-release formulation once-a-day of Coreg a non-selective antagonist of Beta 1, Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors. The Company faces competition from Actavis, Alkermes, BioAlliance Pharma, Depomed, Ethypharm, Octoplus, Veloxis Pharmaceuticals, Nektar Therapeutics. The Company owns and develops drug delivery platforms that are able to tackle key challenges in the formulation, in various dosage forms of a broad range of drugs novel, already-marketed, or off-patent that includes Micropump. During the 2013 the Company has 395 patents in total. The design, testing, manufacturing and marketing of certain new or substantially modified drugs, biological products or medical devices must be approved, cleared or certified by regulatory agencies, regulatory authorities and Notified Bodies under applicable laws and regulations, the requirements of which may vary from country to country.

Ratios

vs
industry
vs
history
P/E(ttm) 17.74
FLML's P/E(ttm) is ranked higher than
67% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. FLML: 17.74 )
Ranked among companies with meaningful P/E(ttm) only.
FLML' s P/E(ttm) Range Over the Past 10 Years
Min: 10.28  Med: 21.37 Max: 36.18
Current: 17.74
10.28
36.18
Forward P/E 53.76
FLML's Forward P/E is ranked lower than
89% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. FLML: 53.76 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 17.74
FLML's PE(NRI) is ranked higher than
69% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. FLML: 17.74 )
Ranked among companies with meaningful PE(NRI) only.
FLML' s PE(NRI) Range Over the Past 10 Years
Min: 10.28  Med: 21.37 Max: 36.18
Current: 17.74
10.28
36.18
Price/Owner Earnings (ttm) 21.39
FLML's Price/Owner Earnings (ttm) is ranked higher than
58% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 28.19 vs. FLML: 21.39 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
FLML' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.32  Med: 27.57 Max: 537.22
Current: 21.39
8.32
537.22
P/B 12.08
FLML's P/B is ranked lower than
88% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. FLML: 12.08 )
Ranked among companies with meaningful P/B only.
FLML' s P/B Range Over the Past 10 Years
Min: 1.84  Med: 5.12 Max: 71.87
Current: 12.08
1.84
71.87
P/S 2.96
FLML's P/S is ranked higher than
79% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. FLML: 2.96 )
Ranked among companies with meaningful P/S only.
FLML' s P/S Range Over the Past 10 Years
Min: 2.03  Med: 5.34 Max: 41.79
Current: 2.96
2.03
41.79
PFCF 12.86
FLML's PFCF is ranked higher than
75% of the 123 Companies
in the Global Biotechnology industry.

( Industry Median: 24.25 vs. FLML: 12.86 )
Ranked among companies with meaningful PFCF only.
FLML' s PFCF Range Over the Past 10 Years
Min: 4.54  Med: 19.85 Max: 154.15
Current: 12.86
4.54
154.15
POCF 12.32
FLML's POCF is ranked higher than
73% of the 186 Companies
in the Global Biotechnology industry.

( Industry Median: 19.60 vs. FLML: 12.32 )
Ranked among companies with meaningful POCF only.
FLML' s POCF Range Over the Past 10 Years
Min: 4.44  Med: 16.07 Max: 51.48
Current: 12.32
4.44
51.48
EV-to-EBIT 4.47
FLML's EV-to-EBIT is ranked higher than
79% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. FLML: 4.47 )
Ranked among companies with meaningful EV-to-EBIT only.
FLML' s EV-to-EBIT Range Over the Past 10 Years
Min: -58.2  Med: -10.9 Max: 6.5
Current: 4.47
-58.2
6.5
EV-to-EBITDA 3.66
FLML's EV-to-EBITDA is ranked higher than
80% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. FLML: 3.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
FLML' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4256.9  Med: -14.1 Max: 1473.8
Current: 3.66
-4256.9
1473.8
Current Ratio 3.01
FLML's Current Ratio is ranked lower than
63% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. FLML: 3.01 )
Ranked among companies with meaningful Current Ratio only.
FLML' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 2.83 Max: 6.76
Current: 3.01
0.83
6.76
Quick Ratio 2.94
FLML's Quick Ratio is ranked lower than
61% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. FLML: 2.94 )
Ranked among companies with meaningful Quick Ratio only.
FLML' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 2.75 Max: 6.7
Current: 2.94
0.74
6.7
Days Inventory 88.75
FLML's Days Inventory is ranked higher than
65% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. FLML: 88.75 )
Ranked among companies with meaningful Days Inventory only.
FLML' s Days Inventory Range Over the Past 10 Years
Min: 51.05  Med: 86.59 Max: 565.95
Current: 88.75
51.05
565.95
Days Sales Outstanding 36.99
FLML's Days Sales Outstanding is ranked higher than
71% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. FLML: 36.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
FLML' s Days Sales Outstanding Range Over the Past 10 Years
Min: 15.78  Med: 74.39 Max: 100.9
Current: 36.99
15.78
100.9
Days Payable 240.74
FLML's Days Payable is ranked higher than
86% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. FLML: 240.74 )
Ranked among companies with meaningful Days Payable only.
FLML' s Days Payable Range Over the Past 10 Years
Min: 168.71  Med: 228.67 Max: 865.73
Current: 240.74
168.71
865.73

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -18.20
FLML's 3-Year Average Share Buyback Ratio is ranked lower than
64% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. FLML: -18.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FLML' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -47.7  Med: -7.8 Max: -0.5
Current: -18.2
-47.7
-0.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 6.78
FLML's Price/Projected FCF is ranked lower than
71% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. FLML: 6.78 )
Ranked among companies with meaningful Price/Projected FCF only.
FLML' s Price/Projected FCF Range Over the Past 10 Years
Min: 4.45  Med: 6.59 Max: 93.64
Current: 6.78
4.45
93.64
Price/Median PS Value 0.55
FLML's Price/Median PS Value is ranked higher than
76% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. FLML: 0.55 )
Ranked among companies with meaningful Price/Median PS Value only.
FLML' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.28  Med: 1.07 Max: 7.08
Current: 0.55
0.28
7.08
Earnings Yield (Greenblatt) (%) 22.49
FLML's Earnings Yield (Greenblatt) (%) is ranked higher than
94% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. FLML: 22.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FLML' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 15.4  Med: 23.5 Max: 38.9
Current: 22.49
15.4
38.9

More Statistics

Revenue (TTM) (Mil) $151.9
EPS (TTM) $ 0.61
Beta1.66
Short Percentage of Float1.76%
52-Week Range $7.56 - 15.54
Shares Outstanding (Mil)41.24

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 143 167 166
EPS ($) -0.09 0.20 0.50
EPS w/o NRI ($) -0.09 0.20 0.50
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for FLML

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
ETFs with exposure to Flamel Technologies SA : December 5, 2016 Dec 05 2016
Is Flamel Technologies S.A. (ADR) (FLML) A Good Stock To Buy? Dec 05 2016
FLAMEL TECHNOLOGIES SA Financials Nov 23 2016
Flamel Technologies SA :FLML-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016 Nov 22 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 17 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 15 2016
FLAMEL TECHNOLOGIES SA Files SEC form 10-Q, Quarterly Report Nov 14 2016
Horizon Pharma PLC (HZNP), Flamel Technologies S.A. (ADR) (FLML) & More: Why Should You Consider... Nov 14 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Other Events Nov 10 2016
Flamel Technologies to Present Jefferies 2016 London Healthcare Conference Nov 09 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K/A, Results of Operations and Financial Condition,... Nov 07 2016
Edited Transcript of FLML earnings conference call or presentation 7-Nov-16 3:00pm GMT Nov 07 2016
CORRECTION - Flamel Technologies Reports Third Quarter 2016 Results Nov 07 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Results of Operations and Financial Condition, Regulation... Nov 07 2016
Flamel reports 3Q loss Nov 07 2016
Flamel reports 3Q loss Nov 07 2016
Flamel Technologies Reports Third Quarter 2016 Results Nov 07 2016
Q3 2016 Flamel Technologies SA Earnings Release - Before Market Open Nov 07 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Other Events Oct 27 2016
Flamel Technologies to Report Third Quarter 2016 Results Oct 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)